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Abstract	
The	pyrrolysine	 tRNA	synthetase-tRNA	pair	 is	 likely	one	of	 the	most	promiscuous	 tRNA-synthetase	
pairs	 found	 in	 nature,	 capable	 of	 genetically	 encoding	 a	 plethora	 of	 non-canonical	 amino	 acids	
through	 stop	 codon	 reassignment.	 Proteins	 containing	 reactive	 handles,	 post-translational	
modification	mimics	or	both	can	be	produced	in	practical	quantities,	allowing	 inter	alia	the	probing	
of	biological	pathways,	the	generation	of	antibody-drug	conjugates,	and	enhancing	protein	function.	
This	 Minireview	 summarises	 the	 development	 of	 pyrrolysine	 amber	 stop	 codon	 suppression,	
presents	some	of	the	considerations	required	to	utilise	this	technique	to	its	greatest	potential,	and	
showcases	the	creative	ways	in	which	this	technique	has	led	to	a	better	understanding	of	biological	
systems.	
1.	Pyrrolysine:	The	22
nd
	Canonical	Amino	Acid	
The	“22
nd
	canonical	amino	acid”	pyrrolysine	(Pyl,	Scheme	1a)	1	is	a	rare	amino	acid	utilised	by	only	a	
handful	 of	 organisms,	 primarily	 archaeal	 methanogens	 of	 the	 Methanosarcinacea	 family.
[1]
	 In	
contrast	to	other	lysine	derivatives	such	as	hypusine	2	and	alkylated/acylated	lysines	3-5	which	are	
post-translational	 modifications	 (PTMs)	 of	 lysine,	 pyrrolysine	 is	 genetically	 encoded,
[2]
	 with	
biosynthesis	occurring	prior	to	translation	(Scheme	1b)	starting	from	lysine	6	via	 intermediates	6a-
c
[3]
	utilising	biosynthetic	enzymes	PylB,
[4]
	PylC
[5]
	and	PylD.
[6]
	The	usage	of	 this	amino	acid	 is	 largely	
confined	 to	 the	active	 site	of	methyltransferases,	wherein	 the	electrophilic	 imine	group	 is	used	 to	
capture	methylamine	and	mediate	the	transfer	of	CH3
+
	 to	cobalt(I)	 in	 the	active	site.
[7]
	A	proposed	
reason	for	the	evolution	of	this	additional	canonical	amino	acid	system	is	the	adaptation	of	various	
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Archaea	 to	 mono/di/trimethylamine-rich	 environments	 such	 as	 cattle	 rumen;
[8]
	 indeed,	 the	
bacterium	 Acetohalobium	 arabaticum	 has	 been	 found	 to	 expand	 its	 genetic	 code	 to	 include	
pyrrolysine	only	in	the	presence	of	trimethylamine.
[9]
	
	
Scheme	1:	A	Native	lysine	derivatives	found	in	proteins;	B	biosynthetic	pathway	of	pyrrolysine.	
Pyrrolysine	 is	encoded	by	 the	amber	 stop	codon,	TAG	 in	DNA	and	CUA	anticodon	on	 tRNA;	hence	
incorporation	 into	 proteins	 has	 necessitated	 overriding	 the	 stop	 function	 of	 this	 codon.	 This	 has	
occurred	 through	 the	 natural	 evolution	 of	 an	 orthogonal	 tRNA-tRNA	 synthetase	 (RS)	 pair	 in	
pyrrolysine-utilising	 organisms.	 Pyrrolysine	 is	 delivered	 to	 the	 ribosome	 during	 translation	 in	 the	
form	 of	 Pyl-tRNA
Pyl
,	 a	 complex	 formed	 through	 the	 charging	 of	 tRNA
Pyl
	 with	 pyrrolysine	 by	 PylRS,	
which	has	the	corresponding	CUA	anticodon.	PylRS	is	a	Class	II	tRNA	synthetase,	a	homodimer	in	the	
active	 form,	with	 an	 amino	 acid	 binding	pocket	which	 extends	deep	 into	 the	protein	 and	 exhibits	
significant	hydrophobic	character	(Figure	1).
[10]
		
	
Figure	1:	the	hydrophobic	amino	acid	binding	pocket	extends	far	inside	PylRS	(Methanosarcina	
mazei).	PDB:	2Q7H.
[10]
	
As	 is	 expected	 of	 a	 tRNA	 synthetase,	 specificity	 for	 the	 substrate	 amino	 acid	 versus	 other	 native	
amino	acids	is	very	high:	no	other	canonical	amino	acids	are	recognised	by	pylRS.	Attempts	to	hijack	
the	 amber	 stop	 codon	 for	 protein	 expression	 in	 E.	 coli	 cells	 using	 the	 tRNA
Pyl
-PylRS	 pair	 in	 the	
absence	of	pyrrolysine	failed,	with	only	truncated	protein	being	produced	even	at	abnormally	high	
A	
B	
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concentrations	 of	 canonical	 amino	 acid,
[11]
	 unequivocally	 demonstrating	 the	 orthogonality	 of	 this	
pair	to	canonical	amino	acids.	
2.	Hijacking	the	Pyrrolysine	System	
As	specific	as	pylRS	may	be	 in	the	pool	of	natural	amino	acids,	 this	enzyme	has	been	shown	to	be	
highly	 promiscuous	 with	 unnatural	 amino	 acids.	 PylRS	 could	 be	 co-crystallised	 with	 not	 only	
pyrrolysine-AMP	 but	 also	 pyrrolysine	 analogue	 7	 and	 ATP	 (Scheme	 2).
[10]
	 Whilst	 the	 addition	 of	
substrate	analogues	is	hardly	uncommon	in	protein	crystallography,	it	was	quickly	realised	that	the	
proteinogenic	role	of	PylRS	could	be	highly	exploitable	if	structural	analogues	of	pyrrolysine	could	be	
recognised	by	pylRS	and	hence	incorporated	into	proteins,
[12]
	analogously	to	other	orthogonal	tRNA-
RS	 pairs
[13]
	 such	 as	 the	Methanocaldococcus	 janaschii	pair	 capable	 of	 introducing	 various	 tyrosine	
analogues	 into	 proteins.
[14]
	 Hence	 simple	 pyrrolysine	 analogues	 8	 and	 9	 were	 successfully	
incorporated	into	β-galactosidase	as	a	test	protein	in	E.	coli.	
[15]
		
	
Scheme	2:	Simple	pyrrolysine	analogues	incorporated	into	proteins.	
The	 limits	 on	 the	 design	 of	 pyrrolysine	 analogues	 chiefly	 arise	 from	 the	 specificity	 of	 PylRS:	 any	
analogue	 must	 have	 some	 affinity	 for	 the	 hydrophobic	 binding	 pocket.	 Key	 interactions	 involve	
Tyr384,	Asn346,	Trp417,	Cys348	and	Val401	inter	alia	in	PylRS	from	M.	mazei	(Figure	2).	The	former	
two	 are	 important	 in	 mediating	 hydrogen	 bonding	 interactions	 between	 the	 α-amino	 group,	 the	
imine	nitrogen	and	the	pyrroline	carbonyl,	whilst	the	latter	three	are	the	main	residues	defining	the	
hydrophobic	pocket.
[16]
	Given	 this	 reasoning,	most	pyrrolysine	analogues	 involve	a	different	amide	
(or	 carbamate)	 on	 the	 ε-amino	 group,	 with	 an	 additional	 hydrogen	 bond	 acceptor	 replacing	 the	
imine	 and	 a	 moderate-size	 hydrophobic	 group	 replacing	 the	 pyrroline	 ring.	 This	 is	 illustrated	 by	
analogues	7-9,	with	a	 common	set	of	analogues	being	dipeptides	 such	as	9.	Notably,	 the	α-amino	
group	 plays	 only	 a	 minor	 role	 in	 substrate	 recognition,	 likely	 acting	 only	 as	 a	 hydrogen	 bond	
Figure	2:	Key	residues	in	the	active	site	of	PylRS	(M.	mazei)	responsible	for	amino	acid	recognition.	
PDB:	2Q7H.
[10]	
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donor/acceptor,	to	the	end	that	pyrrolysine-like	α-hydroxy	acids	are	suitable	substrates	for	PylRS.
[17]
			
Whilst	 the	promiscuity	of	 the	wild-type	PylRS	variants	 from	Methanosarcina	barkeri	and	M.	mazei	
(between	which	the	active	site	residues	are	largely	conserved)	is	already	of	significant	utility,	rational	
enzyme	engineering	has	 further	expanded	the	domain	of	pyrrolysine	analogues.	Whilst	Boc-Lys	10	
and	Aloc-Lys	11	are	suitable	substrates	for	the	wild	type	PylRS,
[18]
	other	lysine	derivatives	such	as	Ac-
Lys	 5,
[19]
	 Z-Lys	 12
[20]
	 and	 AzZ-Lys	 13
[18]
	 with	 traditional	 “protecting	 groups”	 or	 variants	 thereof	
required	 mutations	 to	 the	 active	 site	 (Scheme	 3).	 Incorporating	 the	 small	 derivative	 5	 required	
shrinking	 the	hydrophobic	pocket	 through	a	C313F	mutation,	amongst	other	mutations,	 to	 the	M.	
barkeri	PylRS,	whilst	the	more	hydrophobic	12	and	13	necessitated	the	key	mutations	of	C348V	and	
Y384F	respectively	in	PylRS	from	M.	mazei.		
	
Scheme	3:	Protected	pyrrolysine	analogues.	
Once	a	suitable	pyrrolysine	analogue	has	been	selected,	protein	production	is	governed	by	addition	
of	the	unnatural	amino	acid,	tRNA
Pyl
	and	PylRS.	This	is	typically	achieved	in	a	one-pot	fashion	by	co-
transforming	 genes	 for	 pylRS	 and	 tRNA
Pyl
	 alongside	 the	 gene	 of	 interest	 into	 the	 cell	 line	 and	
inducing	both	genes	during	overexpression	in	the	presence	of	the	unnatural	amino	acid	(Figure	3).	A	
number	of	constructs	have	combined	the	genes	for	tRNA
Pyl
,	PylRS	and	other	expression	factors	into	
single	vectors	for	greater	yields	and	expression	control	in	a	variety	of	cell	lines,
[21]
	as	well	as	making	
use	 of	 evolved	 pyrrolysine	 tRNAs	 for	 further	 improved	 yields,	 even	with	multiple	 reassigned	 stop	
codons.
[22]
	 A	 common	 problem	 experienced	 is	 protein	 truncation	 arising	 from	 translation	
termination	at	 the	 reassigned	codon,	 lowering	protein	yields;	 this	has	been	circumvented	 through	
the	 use	 of	 release	 factor	 one	 (RF1)	 knockout	 strains,
[23]
	 increasing	 protein	 yields	 with	 minimal	
negative	effects	on	the	host	cells.
[24]
	
	
Figure	3:	Amber	stop	codon	suppression	in	recombinant	cells	using	unnatural	amino	acids	and	the	
tRNA
Pyl
-PylRS	pair.	
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3.	PTM	Mimicry	and	Protecting	Groups	
The	expansion	of	the	genetic	code	has	been	used	extensively	in	the	study	of	histones,	in	which	lysine	
residues	frequently	undergo	PTMs	which	have	implications	in	disease	states.	As	discussed,	evolution	
of	 a	 suitable	 PylRS	 permitted	 incorporation	 of	 acetylated	 lysine	 5	 into	 green	 fluorescent	 protein	
(GFP),	 myoglobin
[19]
	 and	 chloramphenicol	 acetyltransferase,
[25]
	 with	 further	 work	 applied	 to	 the	
biological	 target	of	histones.	Histone	H3	was	prepared	with	and	without	K56	acetylation	using	this	
method,
[26]
	 allowing	 a	 full	 evaluation	 of	 acetylation	 in	 various	 processes	 such	 as	 chromatin	
remodelling	 and	 DNA	 breathing	 using	 both	 variants.	 Notably,	 this	 residue	 has	 been	 resistant	 to	
modification	 through	 other	 methods.	 Differentially	 acetylated	 variants	 of	 H2A	 and	 H2B	 subunits	
were	 also	 prepared.	 Optimisation	 of	 this	 method	 later	 allowed	 production	 of	 full-length	 H3	
containing	 four	acetylated	 lysine	 residues	 in	E.	coli	 cells,
[27]
	 and	 further	work	allowed	concomitant	
production	 of	 six	 differentially	 acetylated	 H3	 variants	 directly	 in	 multiple	 mammalian	 cell	 lines,	
demonstrating	the	influence	of	histone	acetylation	on	the	expression	of	particular	genes.
[28]
	
Attempts	to	incorporate	methylated	lysine	3	 into	H3	using	directed	evolution	of	PylRS	were	unable	
to	replicate	the	success	achieved	with	5.	Ingeniously,	a	strategy	was	developed	to	utilise	a	“masked”	
derivative	of	3	 to	achieve	 incorporation:	given	 that	Boc-Lys	10	 can	be	 recognised	by	 the	wild-type	
PylRS
[20]
	and	deprotected	with	dilute	TFA	to	yield	the	free	amine,	it	was	hypothesised	that	the	lysine	
surrogate	14	 should	be	compatible	with	an	analogous	strategy	 to	yield	methylated	 lysine	 (Scheme	
4).	 Indeed,	 incorporation	 and	 post-translational	 deprotection	 yielded	 modified	 myoglobin	 and	
histone	 H3K9me1,
[29]
	 with	 K9	 methylation	 hence	 shown	 to	 be	 essential	 for	 the	 binding	 of	 H3	 to	
heterochromatin	 protein	 1.	 Further	 work	 demonstrated	 how	 this	 route	 could	 be	 used	 to	 install	
multiple	 monomethylated	 lysine	 residues	 in	 histone	 H3	 through	 the	 use	 of	 RF1	 knockout	 E.	 coli	
strain	RF0.
[30]
	A	later	strategy	achieved	the	same	overall	incorporation	of	3	into	a	protein,	but	using	
an	alternative	protecting	group.	As	Alloc-Lys	11	 is	a	suitable	substrate	 for	PylRS,	 the	N-methylated	
derivative	15	could	serve	as	an	analogous	“caged”	precursor	to	3	if	the	Alloc	group	could	be	cleaved	
in	a	bioorthogonal	manner	akin	to	a	Boc	group.	Histone	H2B	was	produced	containing	15	at	position	
27	and	the	post-translational	deprotection	succeeded	with	a	ruthenium	catalyst	and	thiophenol	to	
yield	H2BK27me1.
[31]
	 The	 cleavage	 conditions	 for	 Alloc	 are	 evidently	 preferable	 as	 the	 biologically	
incompatible	 acidic	 conditions	 required	 for	 Boc	 cleavage	 cause	 protein	 denaturation	 and	 require	
refolding	for	further	work,	which	is	not	always	feasible	in	the	case	of	large	or	complex	proteins.	
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Scheme	4:	Installation	of	methylated	lysine	using	amber	stop	codon	suppression,	either	methylated	
Boc-Lys	14	or	Alloc-Lys	15,	and	the	respective	deprotection	conditions.	
The	 installation	 of	 dimethylated	 lysine	 4	 in	 proteins	 has	 been	 a	 far	 more	 elusive	 goal.	 Efforts	 to	
evolve	a	pylRS	recognising	4	 failed,	and	deprotection	strategies	are	not	possible	due	to	the	limited	
valence	 of	 the	 nitrogen	 atom	 and	 the	 instability	 of	 an	 analogous	 quaternary	 ammonium	 salt.	 An	
early	strategy	towards	dimethyllysine-containing	histones	made	use	of	lysine	protecting	groups	and	
reductive	amination,	more	reminiscent	of	a	traditional	synthetic	strategy	(Scheme	5).
[32]
	The	target	
lysine	was	installed	as	Boc-Lys	10,	and	all	12	other	lysine	amines	protected	chemically.	Deprotection	
and	alkylation	afforded	the	dimethylated	lysine	residue,	and	all	other	amines	could	be	deprotected	
to	afford	the	desired	histone.	Whilst	impressive,	this	method	is	somewhat	cumbersome,	and	hence	a	
modified	 strategy	was	designed	 to	 install	4	 in	 a	more	 facile	manner.	 The	UAA	16,	 an	unsaturated	
derivative	of	13,	was	 incorporated	 into	GFP	with	an	engineered	M.	mazei	PylRS	and	the	azido-Cbz	
group	 cleaved	 in	 a	 self-immolative	 reductive	 manner	 using	 TCEP,	 after	 which	 the	 free	 imine	 is	
hydrolysed	to	 leave	an	aldehyde	which	can	undergo	reductive	amination	(Scheme	5).
[33]
	These	two	
strategies	reverse	the	location	of	the	aldehyde	and	amine,	but	the	second	route	offered	a	reduced	
reliance	on	protecting	groups	and	milder	reaction	conditions.		
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Scheme	5:	Dimethyllysine	installed	using	noncanonical	lysine	derivatives,	making	extensive	use	of	
protection/deprotection	strategies.	
In	 addition	 to	methylation	 and	 acetylation,	 histone	 lysine	 residues	 have	 been	 found	modified	 by	
other	 carbonyl	 groups,	 and	 further	 work	 has	 naturally	 involved	 using	 stop	 codon	 suppression	 to	
produce	 such	 modified	 histones.	 Small	 fatty	 acid	 derivatives	 of	 lysine	 17-19	 (Scheme	 6)	 were	
conveniently	found	to	be	substrates	for	wild-type	PylRS,	leading	to	various	K9-acylated	derivatives	of	
H3.
[34]
	 This	 work	 was	 later	 refined	 using	 directed	 evolution	 of	 PylRS,	 leading	 to	 the	 synthesis	 of	
octamers	of	propionylated,	butyrated	and	crotonylated	H4	proteins.	
[35]
	Two	additional	lysine	PTMs	
found	in	native	histones	could	also	be	introduced	using	lysine	derivatives	20
[36]
	and	21,
[37]
	in	addition	
to	 novel	 analogue	 22	 and	 protected	 Piv-Lys	 23,	 with	 directed	 evolution	 of	 PylRS	 again	 proving	
essential.	 A	 creative	 strategy	 to	 incorporate	 acylated	 lysine	 derivatives	 made	 use	 of	
azidohomoleucine	 24	 in	 combination	 with	 on-protein	 traceless	 Staudinger	 ligations	 to	 afford	
acetylated	 and	 photocaged	 succinylated	 lysine	 residues,	 with	 the	 key	 property	 of	 being	 able	 to	
acylate	 independently	 of	 genetic	 code	 expansion	 through	 modifying	 the	 phosphinothioester	
reagent.
[38]
	
	
Scheme	6:	Acylated	lysine	derivatives	or	precursors	compatible	with	PylRS,	either	as	PTM	mimics	or	
of	novel	use.	
The	 ability	 to	 incorporate	 traditional	 organic	 chemistry	 protecting	 groups	 into	 proteins,	 and	
subsequently	deprotect	using	bioorthogonal	reagents,	has	seen	use	beyond	histones.	Following	on	
from	the	use	of	Boc	and	Alloc,	given	that	Z-Lys	12
[20]
	and	oNZ-Lys	25
[39]
	could	be	genetically	encoded,	
protected	 derivatives	 of	 methyllysine	 3	 could	 also	 be	 incorporated	 using	 the	 N-methylated	
derivatives	 of	 12	 and	 25	 which	 are	 unmasked	 by	 palladium
[40]
	 and	 long-wave	 UV	 irradiation
[41]
	
respectively.	These	two	deprotection	steps	are	generally	considered	to	be	bioorthogonal,	although	
the	use	of	UV	radiation	 is	not	desirable	 in	 live	cell	work.	Palladium	deprotection	was	 further	used	
with	Alloc-Lys	15	and	Proc-Lys	26	to	demonstrate	site-specific	caging	of	individual	lysine	residues	in	
proteins	 and	 bioorthogonally	 decaging	 in	 vitro	 and	 in	 vivo,	 with	 the	 application	 of	 palladium-
activated	toxicity	through	release	of	a	key	lysine	residue	in	a	bacterial	toxin.
[42]
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4.	Pyrrolysine	Analogues	in	Click	Chemistry	and	Diels-Alder	Cycloadditions	
Click	chemistry	has	rapidly	become	a	staple	of	bioorthogonal	chemistry:	 its	broad	substrate	range,	
biocompatibility	 and	 stability	of	 coupling	partners	 and	 fast	 kinetics	have	 facilitated	 its	widespread	
adoption	 in	 chemical	 biology.	 Use	 for	 protein	modification	was	 initially	 documented	 using	 a	 viral	
coat	 protein	 non-selectively	 labelled	 with	 an	 azido-acyl	 linker	 which	 subsequently	 underwent	
ligation	with	 alkynyl	 fluorescein	 and	 an	 alkyne-containing	 dansyl-BSA	 conjugate.
[43]
	 This	 first	 foray	
into	 copper-catalysed	 click	 chemistry	 (CuAAC)	 in	 protein	 modification	 was	 an	 unequivocal	
demonstration	of	the	potential	of	the	technique,	albeit	suffering	from	the	drawback	of	a	lack	of	site	
specificity.	 Stop	 codon	 suppression	 is	 a	 near-perfect	 solution	 to	 this	 problem,	 with	 the	 highly	
modifiable	nature	of	both	techniques	being	pleasingly	synergistic.	Azides	and	alkynes	13	and	27-31	
(Scheme	 7)	 have	 been	 encoded	 using	 pyrrolysine	 analogues	 and	 used	 in	 CuAAC	 to	 create	
bioconjugates	 ranging	 from	 fluorophore-tagged	 proteins,
[44]
	 biotinylated	 myoglobin,
[45]
	 reversibly	
SUMOylated	proteins,
[46]
	and	even	functional	antibody-drug	conjugates	(ADCs).	The	development	of	
strain-promoted	azide-alkyne	cycloadditions	(SPAAC)	as	a	“copper-free	click	chemistry”	was	further	
reflected	 in	 additional	 pyrrolysine	 analogues	 developed.	 Strained	 cyclooctyne	 (SCO)	 30
[47]
	 and	
diastereomers	of	bicyclononyne	(BCN)	31
[48]
	opened	up	even	wider	possibilities	for	click	chemistry,	
including	 SPAAC-induced	 amine	 group	 unmasking,
[49]
	 imaging	 of	 HeLa	 cells	without	 the	 additional	
concern	of	cytotoxic	copper	catalysts	and	producing	stable	ADCs	with	anti-cancer	effects	in	mice.
[50]
	
The	rise	of	strain-promoted	 inverse	electron-demand	Diels	Alder	cycloaddition	(SPIEDAC),	 in	which	
strained	dienophiles	such	as	methylcyclopropenes
[51]
	or	31-35	are	coupled	to	tetrazines,	prompted	a	
similar	introduction	of	SPIEDAC-capable	pyrrolysine	analogues,	with	SPIEDAC	offering	the	advantage	
of	 faster	 kinetics	 than	 CuAAC	 and	 SPAAC
[52]
	 whilst	 also	 retaining	 fluorogenicity.	 An	 assortment	 of	
proteins	 containing	 norbornenes	 and	 trans-cyclooctenes	 (TCOs)	 32-35	 could	 be	 produced	 using	
engineered	variants	of	the	M.	mazei	PylRS.	Applications	have	included	fluorescently	tagged	proteins	
in	 vitro,
[53]
	 rapid	 labelling	 of	 proteins	 in	 vivo,
[54]
	 live	 cell	 labelling,
[55]
	 synthesis	 of	 glycoconjugates	
using	 glycosyl	 azides,
[56]
	 protein	 cross-linking,
[57]
	 and	 SPIEDAC-initiated	 rapid	 decaging	 via	 a	 novel	
rearrangement	 mechanism.
[58]
	 Stop	 codon	 suppression	 and	 bioorthogonal	 chemistry	 are	 highly	
complementary	 techniques	 in	 the	 field	 of	 protein	 modification	 and	 have	 facilitated	 innovative	
developments	in	the	field	of	chemical	biology.	
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Scheme	7:	Pyrrolysine	analogues	used	in	click	chemistry,	SPAAC	and	SPIEDAC.	
5.	Recognising	Phenylalanine	and	Cysteine	Analogues	using	Pyrrolysine	tRNA	Synthetase	
Whilst	 lysine	derivatives	are	clearly	highly	useful	 targets	 for	 incorporation	 into	proteins	using	stop	
codon	suppression,	greater	utility	could	be	afforded	through	the	recognition	of	an	even	wider	range	
of	non-canonical	amino	acids	by	the	M.	mazei	PylRS.	Six	key	residues	in	the	active	site-	L305,	Y306,	
L309,	N346,	C348	and	W417-	were	mutated	randomly	and	screened	against	phenylalanine	(Phe)	36	
and	 p-iodo-Phe	 37	 (Scheme	 8).	Whilst	 36	 required	 only	 N346	 and	 C348	mutations	 for	 successful	
incorporation,	the	most	successful	PylRS	with	37	required	mutations	to	five	of	the	six	selected	active	
site	 residues.	GFP	containing	36	and	37	could	be	produced,	and	brominated	analogue	38	was	also	
shown	 to	 be	 a	 substrate	 for	 the	37-recognising	 PylRS.
[59]
	 The	 synthetic	 utility	 of	 this	method	was	
starkly	 shown	 through	 the	 ability	 to	perform	a	 site-specific	 Suzuki-Miyaura	 coupling	between	 a	 Z-
domain	protein	containing	37	and	a	dansylated	boronic	acid.	The	promiscuity	of	the	engineered	M.	
mazei	PylRS	was	further	examined	and,	following	N346A	and	C348A	mutations	(PylRS
AA
),	additional	
Phe	analogues	39-42	proved	to	be	suitable	substrates,	with	39	possessing	the	additional	function	of	
CuAAC	 reactivity.
[60]
	 The	 same	 mutant	 could	 also	 recognise	 an	 array	 of	 meta-substituted	 Phe	
derivatives	43-54,	with	a	range	of	functional	groups	including	halides,	ketones,	alkynes	and	azides.
[61]
	
Trifluoromethylated	 UAA	 48	 found	 instant	 use	 as	 a	 sensitive	
19
F	 handle,	 allowing	 monitoring	 of	
protein	 folding	 states	 through	 NMR	 alongside	 other	 fluorinated	 unnatural	 amino	 acids.
[62]
	 A	 key	
discovery	 was	 the	 ability	 to	 genetically	 encode	 aldehyde	 55	 using	 PylRS
AA
,
[63]
	 producing	 proteins	
which	 can	 undergo	 key	 bioorthogonal	 reactions	 such	 as	 oxime	 ligation.	 Other	 methods	 to	 install	
aldehydes	 into	 proteins	 such	 as	 using	 formylglycine-generating	 enzyme	 (FGE)	 and	 N-terminal	
oxidation	are	less	flexible	in	where	the	aldehyde	can	be	installed,	as	well	as	furnishing	electronically	
different	 aldehydes.
[64]
	 This	 finding	 circumvented	 a	 requirement	 to	 utilise	 the	 pyrrolysine	
biosynthetic	pathway	to	install	aldehydes	in	proteins,	with	previous	work	making	use	of	the	imine	in	
pyrrolysine	 1	 itself,	 and	 its	 demethylated	 analogue,	 as	 aldehyde	 equivalents	 for	 protein	
bioconjugation.
[65]
	Further	work	confirmed	that	the	promiscuity	of	the	PylRS
AA
	mutant	was	such	that	
several	ortho-substituted	phenylalanine	analogues	56-61	could	be	incorporated	into	proteins,	even	
in	 live	cells.
[66]
	Orthogonality	was	generally	 retained	with	PylRS
AA
,	although	some	canonical	36	was	
incorporated	 in	 competition	 with	 the	 desired	 Phe	 analogue.	 It	 is	 worth	 noting	 that	 other	 Phe	
10	
	
analogues	can	be	 incorporated	using	 the	M.	 janaschii	TyrT/TyrRS	pair,
[14]
	 including	37
[67]
	 inter	alia,	
although	the	M.	mazei	and	M.	barkeri	PylT/PylRS	pairs	exhibit	an	overall	greater	level	of	promiscuity.	
	
Scheme	8:	Phenylalanine	and	derivatives	compatible	with	a	mutated	PylRS.	
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Whilst	 other	 tRNA/RS	 pairs	 have	 permitted	 the	 genetic	 encoding	 of	 protected	 cysteine	
derivatives,
[68]
	 the	ability	 to	 incorporate	derivatives	of	unprotected	 cysteine	62	 using	genetic	 code	
expansion	has	also	been	a	highly	sought-after	goal,	given	the	broad	range	of	reactions	in	which	the	
thiol	 group	 can	 participate.	 Protected	 lysine	 thiol	 63	 (Scheme	 9)	 was	 shown	 to	 be	 a	 suitable	
substrate	 for	 a	 mutant	 PylRS	 from	 M.	 barkeri,	 with	 the	 deprotected	 protein	 ready	 for	 native	
chemical	ligation	(NCL)	with	a	ubiquitin	thioester.
[69]
	The	wild	type	M.	barkeri	PylRS	also	recognised	
the	 unprotected	 Cys-Lys	 dipeptides	 64S	 and	64R,	 again	 allowing	 ubiquitination	 using	 NCL.
[70]
	64S,	
with	 stereochemical	 configuration	 matching	 that	 of	 pyrrolysine,	 was	 also	 shown	 to	 be	 a	 better	
substrate	for	this	PylRS	variant	than	diastereomer	64R.	Further	work	demonstrated	the	importance	
of	configuration	and	PylRS	variant	as	the	wild	type	M.	mazei	PylRS	could	recognise	64S	but	not	64R,	
exhibiting	 greater	 sensitivity	 to	 the	 configuration	of	 the	Cys	 chiral	 centre.
[71]
	Directed	evolution	of	
the	M.	barkeri	PylRS	 led	to	 improved	recognition	of	64S	and	64R,	as	well	as	compatibility	with	the	
reactive	 amino	 acid	 65a,	 a	 4-thiazolidine	 derivative	 of	 64R	 (to	 circumvent	 pyruvate	 adduct	
formation)	 which,	 once	 unmasked	 with	 methoxyamine,	 could	 undergo	 bioorthogonal	
cyanobenzothiazole	condensation	with	fluorophores	or	aniline-catalysed	thiazolidine	formation	with	
aldehyde-tagged	ubiquitin	(Scheme	10).
[72]
	The	analogous	2-thiazolidine	65b,	used	with	wild-type	M.	
barkeri	 pylRS	 as	 a	 racemate,	 was	 also	 found	 to	 be	 a	 useful	 cage	 for	 reactivity.	 Silver-mediated	
cleavage	 exposed	 a	 glyoxyl	 aldehyde	 capable	 of	 undergoing	 oxime	 ligation,	 although	 notably	 the	
thiazolidine	cleavage	step	required	harsh	protein-denaturing	conditions.	
[73]
		Photocaged	cysteine	66	
could	 be	 installed	 using	 a	 mutant	M.	 barkeri	 PylRS	 without	 the	 need	 for	 a	 lysine	 backbone,
[74]
	
allowing	 the	 controlled	 photoactivation	 of	 the	 catalytic	 cysteine	 residue	 in	 tobacco	 etch	 virus	
protease.
[75]
		
Scheme	9:	Cysteine	and	surrogates	used	in	protein	modification.	
6.	Further	Applications	of	Pyrrolysine	Analogues	
In	addition	to	the	previously	discussed	applications	of	PTMs,	ADCs	and	live	cell	labelling,	the	tRNA
Pyl
-
PylRS	 pair	 has	 seen	 use	 in	 wider	 studies	 such	 as	 photochemistry,	 in	 ventures	 beyond	 the	 initial	
photocaging	strategies	used	with	pyrrolysine	analogues	25
[76]
	and	67
[77]
	and	the	fluorescent	analogue	
68	(Scheme	11).
[78]
	The	introduction	of	photo-crosslinking	amino	acid	69	 into	the	genetic	code	was	
used	to	produce	dimers	of	mutated	glutathione	S-transferase	in	live	cells,	with	the	short	(10-20	min)	
Scheme	10:	Bioorthogonal	of	thiazolidines	incorporated	using	genetic	expansion	techniques.	
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reaction	 times	 permitting	 the	 use	 of	 long-wave	 UV	 irradiation	 in	 live	 cells	 with	 minimal	
interference.
[79]
	Crosslinking	was	also	possible	in	live	cells	between	kinase	Cdk5	containing	69	and	its	
substrate	 kinase	 Pak1,	 demonstrating	 the	 phosphorylation	 cascade	 occurring	 between	 these	 two	
kinases,	 albeit	 with	 the	 unwanted	 side-reaction	 of	 homodimerisation.
[80]
	 Milder	 photochemical	
activation	could	be	achieved	using	70	 in	 the	presence	of	biocompatible	photosensitiser	methylene	
blue	and	oxygen,	forming	a	reactive	enedione	species	in	situ.
[81]
	70	was	installed	in	an	arginine-rich	
motif	 of	 HIV-1	 trans-activator	 of	 transcription	 (TAT)	 protein,	 the	motif	 responsible	 for	 binding	 to	
trans-activation	 response	 RNA	 (TAR),	 and	 upon	 irradiation	 with	 red	 light	 in	 the	 presence	 of	
methylene	blue	and	oxygen	the	covalent	TAT-TAR	complex	was	formed	in	vitro.		
Another	 field	making	 intelligent	use	of	 amber	 stop	 codon	 suppression	 is	 enzyme	engineering.	 The	
activity	of	 an	enzyme	 is	naturally	dependent	on	active	 site	 residues,	 and	hence	mutations	 in	 such	
residues	 can	 impede	 or	 improve	 enzyme	 performance.	 Stop	 codon	 suppression	 allows	 such	
mutations	 to	 include	 non-canonical	 amino	 acids	 to	 further	 allow	 e.g.	 fine-tuning	 of	 hydrogen	
bonding,	 the	 pKa	 values	 of	 residues	 or	 metal	 chelation	 beyond	 that	 of	 the	 canon.	 Methylated	
histidine	(His)	71,	along	with	other	His	analogues	72-75,	have	been	found	to	be	taken	up	by	a	PylRS	
mutant	 engineered	 to	 contain	 an	 amino	 acid	 binding	 site	 much	 smaller	 than	 the	 wild	 type,	 and	
incorporation	 into	 blue	 fluorescent	 protein	 resulted	 in	 altered	 protein	 UV-visible	 spectral	
characteristics,
[82]
	as	has	been	observed	with	canonical	amino	acid	mutagenesis	of	blue	fluorescent	
protein.	 This	 was	 found	 to	 be	 useful	 in	 the	 engineering	 of	 ascorbate	 peroxidase	 APX2,	 where	
introduction	of	71	 in	the	active	site	had	the	effect	of	greatly	increasing	the	enzyme	turnover	in	the	
oxidation	of	guaiacol	and	a	slight	overall	increase	in	catalytic	efficiency.
[83]
	The	exact	reason	for	this	
has	not	been	definitively	elucidated,	but	disruption	of	the	hydrogen	bonding	 in	the	active	site	and	
additional	stabilisation	of	radical	 intermediates	through	hyperconjugation	are	suspected	to	explain	
the	 greater	 stability	 of	 the	 APX2	 mutant.	 Thus,	 non-canonical	 amino	 acid	 mutagenesis	 has	 clear	
potential	in	the	fields	of	enzyme	engineering	and	mechanistic	studies,	offering	far	more	flexibility	in	
retuning	an	enzyme	active	site.	
	
Scheme	11:	Non-canonical	amino	acids	used	in	photochemistry	or	as	histidine	analogues.	
7.	Reflection	and	Outlook	
Chemical	biology	has	benefited	greatly	from	the	pyrrolysine	amber	stop	codon	suppression	system.	
In	 tandem	 with	 bioorthogonal	 reactions	 such	 as	 SPAAC,	 SPIEDAC	 and	 palladium-catalysed	 cross-
coupling	 reactions,	 a	 wealth	 of	 new	 site-specific	 yet	 broadly	 applicable	 protein	 modification	
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strategies	have	been	developed	in	vitro.	Even	protein	modification	and	labelling	in	vivo,	prokaryotic	
and	eukaryotic,	has	become	a	feasible	reality.	The	pyrrolysine	tRNACUA-RS	pair	is	able	to	genetically	
encode	a	far	broader	range	of	amino	acid	analogues	than	other	stop	codon	suppression	pairs.	The	
M.	 janaschii	pair,	whilst	generally	offering	higher	protein	yields,	suffers	some	drawbacks,	 including	
smaller	 substrate	 scope	 and	 incompatibility	 with	 eukaryotic	 cell	 lines,
[84]
	 although	 engineered	
eukaryotic	cell	lines	have	been	used	in	the	successful	generation	of	antibody-drug	conjugates.
[85]
	For	
the	task	of	installing	bioorthogonal	handles,	pyrrolysine	analogues	present	an	attractive	route	as	the	
only	 sequence	 constraint	 is	 the	 stop	 codon	 requirement,	whilst	 other	 enzymatic	methods	 such	 as	
FGE-catalysed	elimination	frequently	require	recognition	sequences.	Previous	chemical	methods	to	
install	 azides	 by	 protein	 acylation	 have	 been	 made	 entirely	 redundant	 due	 to	 the	 lack	 of	 site	
specificity	 compared	 to	 that	 inherent	 in	 the	 pyrrolysine	 amber	 stop	 codon	 suppression	 system.	
Expansion	 of	 the	 genetic	 code	 from	 22	 to	 over	 70	 amino	 acids	 has	 also	 permitted	 exploration	 of	
numerous	biological	systems	impervious	to	previous	human	intervention,	and	will	continue	to	be	a	
source	of	inspiration	and	innovation.	
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MINIREVIEW 
The pyrrolysine tRNA synthetase-
tRNA pair is capable of genetically 
encoding a plethora of non-canonical 
amino acids through amber stop 
codon suppression. This Minireview 
summarises the development of 
pyrrolysine amber stop codon 
suppression, presents some of the 
considerations required to utilise this 
technique to its greatest potential, and 
showcases the creative ways in which 
this technique has led to a better 
understanding of biological systems. 
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